Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
- Dr. Renetta Weaver Makes AI Simple at ClinicianFest 2025
Download
(Photo: Business Wire)
BALTIMORE, Md.--(BUSINESS WIRE)--A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.
More on Marylandian
Lp(a) is similar to "bad" LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles. This makes it even stickier than LDL and more likely to cause blockages and blood clots in blood vessels. Heart attack or stroke are some of the serious and, unfortunately, common cardiovascular events associated with elevated Lp(a). According to the Baltimore City Health Department, heart disease is the leading cause of death and stroke is the third leading cause of death in Baltimore.
KRAKEN is a phase 2 study to assess the efficacy of a new investigational treatment developed to safely and effectively lower Lp(a) in individuals at high risk for cardiovascular events.
"It's estimated that about one in five people in the world have elevated Lp(a) levels with Black people of sub-Saharan descent and South Asians exhibiting even higher rates," said Dr. Ali Bajwa, Principal Investigator of Care Access - Baltimore. "Since elevated Lp(a) is thought to be genetically derived, normal courses of action to treat high cholesterol like eating a healthier diet, exercise, and weight loss have little to no effect on Lp(a) levels. That's why I am very excited to help bring this Lp(a) screening opportunity and investigational treatment to the Baltimore community as a part of this far-reaching study."
The research study is currently enrolling for adults ages 40+ with elevated Lp(a) and at high risk for cardiovascular events. To learn more about this study, visit knowmylpa.com or contact Care Access at (351) 222-5112.
Care Access opened its Baltimore location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the Baltimore community.
More on Marylandian
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study's reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
Contacts
Joseph Oh
media@careaccess.com
202-970-6885
Release Summary
A cardiovascular research study in Baltimore, Maryland, is assessing a potential treatment for elevated Lp(a), a cholesterol not routinely tested for.
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
Social Media Profiles
Contacts
Joseph Oh
media@careaccess.com
202-970-6885
(Photo: Business Wire)
BALTIMORE, Md.--(BUSINESS WIRE)--A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.
More on Marylandian
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
Lp(a) is similar to "bad" LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles. This makes it even stickier than LDL and more likely to cause blockages and blood clots in blood vessels. Heart attack or stroke are some of the serious and, unfortunately, common cardiovascular events associated with elevated Lp(a). According to the Baltimore City Health Department, heart disease is the leading cause of death and stroke is the third leading cause of death in Baltimore.
KRAKEN is a phase 2 study to assess the efficacy of a new investigational treatment developed to safely and effectively lower Lp(a) in individuals at high risk for cardiovascular events.
"It's estimated that about one in five people in the world have elevated Lp(a) levels with Black people of sub-Saharan descent and South Asians exhibiting even higher rates," said Dr. Ali Bajwa, Principal Investigator of Care Access - Baltimore. "Since elevated Lp(a) is thought to be genetically derived, normal courses of action to treat high cholesterol like eating a healthier diet, exercise, and weight loss have little to no effect on Lp(a) levels. That's why I am very excited to help bring this Lp(a) screening opportunity and investigational treatment to the Baltimore community as a part of this far-reaching study."
The research study is currently enrolling for adults ages 40+ with elevated Lp(a) and at high risk for cardiovascular events. To learn more about this study, visit knowmylpa.com or contact Care Access at (351) 222-5112.
Care Access opened its Baltimore location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the Baltimore community.
More on Marylandian
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Community Reintroduction & Rebranding Announcement
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study's reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
Contacts
Joseph Oh
media@careaccess.com
202-970-6885
Release Summary
A cardiovascular research study in Baltimore, Maryland, is assessing a potential treatment for elevated Lp(a), a cholesterol not routinely tested for.
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
- #ClinicalTrials (https://twitter.com/hashtag/ClinicalTrials?src=hash)
- #ClinicalResearch (https://twitter.com/hashtag/ClinicalResearch?src=hash)
Social Media Profiles
- Care Access on Twitter (https://twitter.com/Care_Access_)
- Care Access on LinkedIn (https://www.linkedin.com/company/careaccess)
Contacts
Joseph Oh
media@careaccess.com
202-970-6885
Filed Under: Business
0 Comments
Latest on Marylandian
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Maryland Department of Agriculture Tree Planting Incentives Still Available
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- HomeCentris Healthcare Relocates and Expands Salisbury Office to Support Growth and Enhance Caregiver Resources
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
- "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- Events by Dubsdread Expands Services to The Venue at Lake Lily
- London Gala Emphasizes Trade, FDI and Ongoing Cooperation
- Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
- Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
- Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
- Sea Fox® 368X "Extreme Edition" by Black Label Marine Group Celebrates 5 Years of the Commander Legacy
- CCHR Florida: Mental Health Awareness Month Open House